Author Affiliations: Francis I. Proctor Foundation and Department of Ophthalmology, University of California, San Francisco (Ms Chen and Drs Margolis and Keenan); and Department of Ophthalmology, Chiang Mai University (Drs Somsanguan Ausayakhun, Tangmonkongvoragul, and Sakarin Ausayakhun) and Department of Ophthalmology, Nakornping Hospital (Dr Jirawison), Chiang Mai, Thailand.
Cytomegalovirus (CMV) retinitis is an important cause of blindness among individuals with human immunodeficiency virus (HIV) and AIDS.1 While the prevalence has decreased in some countries owing to widespread antiretroviral therapy, CMV retinitis is still found in up to one-third of patients with HIV and AIDS in Southeast Asia.2,3 Screening for CMV retinitis is important for the prevention of blindness, but it is unclear how frequently patients should be rescreened after having negative results on an initial examination, especially in settings with good access to antiretroviral therapy.
In this retrospective study, we identified and reviewed the records of all patients with HIV seen for an initial screening examination for CMV retinitis at the Ocular Infectious Diseases Clinic, Chiang Mai University, Chiang Mai, Thailand, from July 6, 2006, to December 24, 2009. Collected data included diagnosis of CMV retinitis, age, sex, CD4 lymphocyte count, visual acuity, presence of HIV retinopathy, and treatment with antiretroviral drugs. We calculated the incidence of CMV retinitis in patients who initially had negative results on a screening examination, stratified by baseline characteristics. We used the Mantel-Haenszel rate ratio to assess for risk factors associated with incident CMV retinitis following negative results on an initial screening examination. Ethical approval was obtained from the Research Ethics Committee at Chiang Mai University and from the Committee for Human Research at the University of California, San Francisco.
Of 597 patients with HIV identified, 469 patient records were available for review. On initial examination, 238 of these patients were diagnosed as having CMV retinitis and 22 had non–CMV retinitis pathological findings. Of the remaining 195 patients, 127 were examined at least once more. Seven of these patients were subsequently diagnosed as having CMV retinitis (incidence, 3.7/100 person-years; 95% CI, 1.8-7.8), 4 of whom developed bilateral disease. Retinitis in these 11 eyes was characterized by peripheral involvement (no optic disc or macular involvement in 10 eyes), small lesion size (<10% of retinal surface area in 6 eyes), and good visual acuity (≥20/40 in 6 eyes). The median time until diagnosis was 5.1 months (interquartile range, 2.3-27.8 months). At the time of diagnosis, all patients were receiving antiretroviral agents (median duration of therapy, 3.0 months; interquartile range, 1.0-16.3 months), although the self-reported CD4 lymphocyte count remained below 100/μL (to convert to ×109 per liter, multiply by 0.001) in 5 patients.
The Table summarizes the incidence of CMV retinitis stratified by baseline characteristics. Patients not receiving antiretroviral agents at the initial screening were significantly more likely to develop CMV retinitis (rate ratio = 13.39; 95% CI, 2.62-68.45). Also, CMV retinitis was more common in patients with a CD4 lymphocyte count below 100/μL, although this relationship did not achieve statistical significance (rate ratio = 5.90; 95% CI, 0.73-47.63).
At a medical center in Thailand responsible for the care of all CMV retinitis cases in Chiang Mai, CMV retinitis was diagnosed infrequently after negative results on an initial screening examination—approximately 4% per year. This incidence is higher than that currently seen in the United States (0.24/100 person-years),4 consistent with what is believed to be a higher prevalence of CMV retinitis in Southeast Asia.2 The severity of CMV retinitis in these patients was milder than that of the retinitis detected on initial screening, likely because it was identified early owing to routine screening.5 As expected, patients not receiving antiretroviral agents at the time of initial screening were at greater risk for subsequent development of CMV retinitis.
Limitations of the study include its retrospective nature, the low number of CMV retinitis cases after initial screening, and the proportion of patients lost to follow-up (35%) or missing medical records (21%). Referral bias also limits the study because patients in this setting tend to not receive routine CMV retinitis screening but instead are referred to the clinic when visual symptoms manifest.
In summary, 97.1% of patients with CMV retinitis examined in Chiang Mai were diagnosed as having CMV retinitis at the initial screening visit, suggesting that a single screening examination may be sufficient to diagnose the vast majority of CMV retinitis cases in this setting. Ophthalmologic screening remains important to prevent blindness from CMV retinitis.
Correspondence: Dr Keenan, Medical Sciences Bldg S-310, 513 Parnassus Ave, Box 0412, University of California, San Francisco, San Francisco, CA 94143-0412 (email@example.com).
Author Contributions: Dr Keenan had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This work was supported by the Gladstone Institute of Virology and Immunology Center for AIDS Research and the Research Evaluation and Allocation Committee, University of California, San Francisco, by grant K23EY019071 from the National Eye Institute, and by That Man May See, the Littlefield Trust, the Peierls Foundation, and the Doris Duke Charitable Foundation.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.